Regulation - Botox

Filter

Current filters:

Botox

Popular Filters

Allergan closes $65 million deal with Medytox

Allergan closes $65 million deal with Medytox

09-01-2014

This week US drugmaker Allergan (NYSE: AGN) announced that it has closed a $65 million license agreement…

AllerganAsia-PacificBotoxDermatologicalsLicensingMedytoxPharmaceuticalRegulationUKUSA

UK MHRA licenses Allergan's Botox for use in patients with overactive bladder

11-09-2013

Botox (botulinum toxin type A), from US drugmaker Allergan (NYSE: AGN), has been licensed by the UK Medicines…

AllerganBotoxEuropeGenito-urinaryPharmaceuticalRegulation

FDA approves Allergan's Botox for OAB and NuPathe's Zecuity for migraine

21-01-2013

US drugmaker Allergan (NYSE: AGN) says that the US Food and Drug Administration has approved its Botox…

AllerganBotoxGenito-urinaryNeurologicalNorth AmericaNuPathePharmaceuticalRegulationZecuity

UK's NICE negative on Sanofi's Jevtana, but backs Botox for migraine

11-05-2012

Confirming previous negative guidance (The Pharma Letter January 12), UK drugs watchdog the National…

AllerganBotoxEuropeJevtanaNeurologicalOncologyPharmaceuticalPricingRegulationSanofi

Botox shows efficacy in idiopathic overactive bladder, says Allergan

29-03-2012

USA-based Allergan (NYSE: AGN) announced that two Phase III clinical trials of Botox (onabotulinumtoxinA),…

AllerganBotoxGenito-urinaryPharmaceuticalRegulationResearch

UK NICE asks for more data on Tarceva, and Botox for migraine

17-02-2012

UK drug watchdog the National Institute for Health and Clinical Excellence (NICE) today issued new draft…

AllerganBotoxEuropeNeurologicalOncologyPharmaceuticalPricingRegulationRocheTarceva

Back to top